Promise and Implementation of Proteomic Prostate Cancer Biomarkers.

ABSTRACT: Prostate cancer is one of the most commonly diagnosed malignancy and the fifth leading cause of cancer mortality in men. Despite the broad use of prostate-specific antigen test that resulted in an increase in number of diagnosed cases, disease management needs to be improved. Proteomic biomarkers alone and or in combination with clinical and pathological risk calculators are expected to improve on decreasing the unnecessary biopsies, stratify low risk patients, and predict response to treatment. To this end, significant efforts have been undertaken to identify novel biomarkers that can accurately discriminate between indolent and aggressive cancer forms and indicate those men at high risk for developing prostate cancer that require immediate treatment. In the era of "big data" and "persona

SUBMITTER: Latosinska A 

PROVIDER: S-EPMC6174350 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature